185P - Retrospective study of tumour responses and toxicities associated with anti-PD1 antibody therapy in elderly cancer patients(>75yo) in comparison to patients ≤75yo with metastatic non-small cell lung cancer

Advanced NSCLC

185P - Retrospective study of tumour responses and toxicities associated with anti-PD1 antibody therapy in elderly cancer patients(>75yo) in comparison to patients ≤75yo with metastatic non-small cell lung cancer

Authors

LI CHIA CHONG (AU)
Nadia Corsini (AU)
Jonathon Hogan-Doran (AU)
Michael Brown (AU)

Presenter

LI CHIA CHONG (AU)

Abstract

Abstract

Background

Antibodies directed against PD1 (anti PD1) are approved in Australia for the second line treatment of metastatic non-small cell lung cancer (met NSCLC). There is limited data on the efficacy and tolerability of anti-PD1 in elderly cancer patients. The purpose of this study was to retrospectively evaluate the responses and toxicities in elderly (>75yo) compared with younger patients (≤ 75yo) with met NSCLC treated with anti-PD1.

Methods

56 patients (36 patients ≤75yo; 20 patients >75yo) with metastatic non-small cell lung carcinoma treated with anti-PD1 at Royal Adelaide Hospital, Australia, between January 2010 to January 2017 were retrospectively identified. Patient demographics, metastatic non-small cell lung cancer characteristics, response rates, toxicity profiles and survival data were collected. Statistical comparisons were made between the older (>75yo) and younger (≤75yo) patients.

Results

Adenocarcinoma was the most common histological type of non-small cell lung cancer in both groups. Patients that achieved stable disease in ≤75yo (20/36, 55.6%) were slightly lower compared with >75yo (15/20, 75%). Patients that progressed on anti-PD1 were higher in ≤75yo (12/36, 33.3%) compared with >75yo (5/20, 25%). Median overall survival (OS) and progression-free survival (PFS) was 8.0 months (95% CI, 0.00 to 16.6 months) and 5.0 months (95% CI, 1.47 to 8.53 months), respectively, in the ≤75yo group and 20.0 months (95% CI, 9.2 to 30.8 months) and 6.0 months (95% CI, 4.55 to 7.45 months), respectively, in the >75yo. The log-ranked test indicates that the survival distributions do not differ for OS or PFS (OS, p = .88 and PFS, p > .05). The rates of adverse events were similar between both groups with the most common adverse event being rash and fatigue (grade 1–2). Anti-PD1 treatment discontinuation occurred in 26/36 (72.2%) of ≤75yo and 17/20 (85%) of >75yo. Main reason for treatment discontinuation was progression of disease, 23/36 (63.9%) of ≤75yo and 15/20 (75%) of >75yo.

Conclusions

Anti-PD1 antibodies are safe and effective in elderly patients with metastatic non-small cell lung cancer. Response rate and toxicity profiles are similar between ≤75yo and >75yo.